Xeris Biopharma Holdings (XERS) Gross Profit (2020 - 2026)

Xeris Biopharma Holdings' Gross Profit history runs 7 years deep, the most recent figure standing at $72.6 million for Q1 2026.

• Quarterly Gross Profit rose 41.18% year-over-year to $72.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $270.4 million (up 47.81% YoY) and the FY2025 annual result came in at $249.3 million, up 49.95% from the prior year.
• Gross Profit was $72.6 million for Q1 2026 at Xeris Biopharma Holdings, down from $74.9 million in the prior quarter.
• Across five years, Gross Profit topped out at $74.9 million in Q4 2025 and bottomed at $15.8 million in Q1 2022.
• A 5-year average of $41.8 million and a median of $40.1 million in 2023 frame the typical range for Gross Profit.
• Annual changes were most pronounced in 2022 — Gross Profit soared 271.1% — and 2024, when it increased 1.39%.
• Xeris Biopharma Holdings' Gross Profit stood at $26.9 million in 2022, then jumped by 37.12% to $36.8 million in 2023, then soared by 37.48% to $50.6 million in 2024, then soared by 47.88% to $74.9 million in 2025, then retreated by 3.08% to $72.6 million in 2026.
• Business Quant data shows XERS's Gross Profit at $72.6 million in Q1 2026, $74.9 million in Q4 2025, and $63.4 million in Q3 2025.